ETrade Capital Management’s Outlook Therapeutics OTLK Stock Holding History

ETrade Capital Management’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$35K	Buy	+2,423	New	+$54K	﹤0.01%	865

Other funds holding OTLK

LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

ETrade Capital Management's OTLK Position: Q3 2020 in Review

ETrade Capital Management opened a new position in Outlook Therapeutics (OTLK) in Q3 2020: 2,423 shares worth $35K. The stake represents ﹤0.01% of the portfolio and ranks #865 among its holdings.

27 funds tracked by Wall St. Rank hold OTLK as of Q3 2020.

ETrade Capital Management held 2,423 shares of Outlook Therapeutics worth $35K as of Q3 2020.
Outlook Therapeutics was a new ETrade Capital Management position in Q3 2020.
Outlook Therapeutics made up ﹤0.01% of ETrade Capital Management's portfolio in Q3 2020, its #865 holding.
27 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q3 2020.

Based on ETrade Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.